Publication | Open Access
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
115
Citations
16
References
2014
Year
This study provides Class IV evidence that in patients with recurrent or progressive meningioma, pasireotide LAR does not significantly increase the proportion of patients with PFS at 6 months.
| Year | Citations | |
|---|---|---|
Page 1
Page 1